Chieh-Yu Lin1,2, Sujay Vennam1, Natasha Purington3, Eric Lin1, Sushama Varma1, Summer Han3, Manisha Desa4, Tina Seto5, Nicholas J Wang6, Henning Stehr1, Megan L Troxell1, Allison W Kurian7, Robert B West8. 1. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 2. Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA. 3. Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, CA, USA. 4. Department of Medicine and of Biomedical Data Science, Quantitative Sciences Unit, Stanford University, Stanford, CA, USA. 5. Research Information Technology, Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA. 7. Departments of Medicine and of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA. 8. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. rbwest@stanford.edu.
Abstract
PURPOSE: The detection rate of breast ductal carcinoma in situ (DCIS) has increased significantly, raising the concern that DCIS is overdiagnosed and overtreated. Therefore, there is an unmet clinical need to better predict the risk of progression among DCIS patients. Our hypothesis is that by combining molecular signatures with clinicopathologic features, we can elucidate the biology of breast cancer progression, and risk-stratify patients with DCIS. METHODS: Targeted exon sequencing with a custom panel of 223 genes/regions was performed for 125 DCIS cases. Among them, 60 were from cases having concurrent or subsequent invasive breast cancer (IBC) (DCIS + IBC group), and 65 from cases with no IBC development over a median follow-up of 13 years (DCIS-only group). Copy number alterations in chromosome 1q32, 8q24, and 11q13 were analyzed using fluorescence in situ hybridization (FISH). Multivariable logistic regression models were fit to the outcome of DCIS progression to IBC as functions of demographic and clinical features. RESULTS: We observed recurrent variants of known IBC-related mutations, and the most commonly mutated genes in DCIS were PIK3CA (34.4%) and TP53 (18.4%). There was an inverse association between PIK3CA kinase domain mutations and progression (Odds Ratio [OR] 10.2, p < 0.05). Copy number variations in 1q32 and 8q24 were associated with progression (OR 9.3 and 46, respectively; both p < 0.05). CONCLUSIONS: PIK3CA kinase domain mutations and the absence of copy number gains in DCIS are protective against progression to IBC. These results may guide efforts to distinguish low-risk from high-risk DCIS.
PURPOSE: The detection rate of breast ductal carcinoma in situ (DCIS) has increased significantly, raising the concern that DCIS is overdiagnosed and overtreated. Therefore, there is an unmet clinical need to better predict the risk of progression among DCIS patients. Our hypothesis is that by combining molecular signatures with clinicopathologic features, we can elucidate the biology of breast cancer progression, and risk-stratify patients with DCIS. METHODS: Targeted exon sequencing with a custom panel of 223 genes/regions was performed for 125 DCIS cases. Among them, 60 were from cases having concurrent or subsequent invasive breast cancer (IBC) (DCIS + IBC group), and 65 from cases with no IBC development over a median follow-up of 13 years (DCIS-only group). Copy number alterations in chromosome 1q32, 8q24, and 11q13 were analyzed using fluorescence in situ hybridization (FISH). Multivariable logistic regression models were fit to the outcome of DCIS progression to IBC as functions of demographic and clinical features. RESULTS: We observed recurrent variants of known IBC-related mutations, and the most commonly mutated genes in DCIS were PIK3CA (34.4%) and TP53 (18.4%). There was an inverse association between PIK3CA kinase domain mutations and progression (Odds Ratio [OR] 10.2, p < 0.05). Copy number variations in 1q32 and 8q24 were associated with progression (OR 9.3 and 46, respectively; both p < 0.05). CONCLUSIONS: PIK3CA kinase domain mutations and the absence of copy number gains in DCIS are protective against progression to IBC. These results may guide efforts to distinguish low-risk from high-risk DCIS.
Entities:
Keywords:
Breast cancer; Copy number variant; Ductal carcinoma in situ; PIK3CA
Authors: Alexander Miron; Maria Varadi; Daniel Carrasco; Hailun Li; Lauren Luongo; Hee Jung Kim; So Yeon Park; Eun Yoon Cho; Gretchen Lewis; Sarah Kehoe; J Dirk Iglehart; Deborah Dillon; D Craig Allred; Laura Macconaill; Rebecca Gelman; Kornelia Polyak Journal: Cancer Res Date: 2010-06-15 Impact factor: 12.701
Authors: Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark Journal: J Natl Cancer Inst Date: 2011-03-11 Impact factor: 13.506
Authors: D C Allred; G M Clark; R Molina; A K Tandon; S J Schnitt; K W Gilchrist; C K Osborne; D C Tormey; W L McGuire Journal: Hum Pathol Date: 1992-09 Impact factor: 3.466
Authors: Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz Journal: Nat Biotechnol Date: 2013-02-10 Impact factor: 54.908
Authors: Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling Journal: Nat Rev Cancer Date: 2022-10-19 Impact factor: 69.800
Authors: Fresia Pareja; David N Brown; Ju Youn Lee; Arnaud Da Cruz Paula; Pier Selenica; Rui Bi; Felipe C Geyer; Andrea Gazzo; Edaise M da Silva; Mahsa Vahdatinia; Anthe A Stylianou; Lorenzo Ferrando; Hannah Y Wen; James B Hicks; Britta Weigelt; Jorge S Reis-Filho Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Daniela Nachmanson; Adam Officer; Hidetoshi Mori; Jonathan Gordon; Mark F Evans; Joseph Steward; Huazhen Yao; Thomas O'Keefe; Farnaz Hasteh; Gary S Stein; Kristen Jepsen; Donald L Weaver; Gillian L Hirst; Brian L Sprague; Laura J Esserman; Alexander D Borowsky; Janet L Stein; Olivier Harismendy Journal: NPJ Breast Cancer Date: 2022-01-13